Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May-Jun;15(3):e1867.
doi: 10.1002/wnan.1867. Epub 2022 Oct 28.

Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials

Allison N DuRoss  1 , Jack Phan  2 , Alexander J Lazar  3 , Joshua M Walker  4 , Alexander R Guimaraes  5 , Carole Baas  6 , Sunil Krishnan  7 , Charles R Thomas Jr  4   8 , Conroy Sun  1   4 , Alexander F Bagley  2   4   9
Affiliations
Review

Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials

Allison N DuRoss et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 May-Jun.

Abstract

Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Keywords: dose enhancement; metal nanoparticles; nanoparticle; radiosensitizer.

PubMed Disclaimer

References

REFERENCES

    1. Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., Kim, H., Axelrod, R., Silverman, C. C., Redmond, K. P., & Gillison, M. L. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine, 363(1), 24-35. https://doi.org/10.1056/NEJMoa0912217
    1. Baer, D. R. (2018). The Chameleon effect: Characterization challenges due to the variability of nanoparticles and their surfaces. Frontiers in Chemistry, 6, 145.
    1. Bagley, A. F., Ludmir, E. B., Maitra, A., Minsky, B. D., Li Smith, G., Das, P., Koong, A. C., Holliday, E. B., Taniguchi, C. M., Katz, M. H. G., Tamm, E. P., Wolff, R. A., Overman, M. J., Patel, S., Kim, M. P., Tzeng, C.-W. D., Ikoma, N., Bhutani, M. S., & Koay, E. J. (2022). NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clinical and Translational Radiation Oncology, 33, 66-69. https://doi.org/10.1016/j.ctro.2021.12.012
    1. Bonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., Sarkouh, R. A., Dimitriu, M., Borghi, E., Levy, L., Deutsch, E., & Soria, J.-C. C. (2017). First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas. Clinical Cancer Research, 23(4), 908-917. https://doi.org/10.1158/1078-0432.CCR-16-1297
    1. Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., Moreno, V., Li, R. K., Tiangco, B., Herraez, A. C., Gronchi, A., Mangel, L., Sy-Ortin, T., Hohenberger, P., de Baère, T., … Papai, Z. (2019). NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2-3, randomised, controlled trial. The Lancet Oncology, 20, 1148-1159. https://doi.org/10.1016/S1470-2045(19)30326-2

LinkOut - more resources